Evaluation of Convenience and Compliance of the Easypod™ Electronic Self-injector
Launched by MERCK KGAA, DARMSTADT, GERMANY · Aug 19, 2008
Trial Information
Current as of June 10, 2025
Completed
Keywords
ClinConnect Summary
An international, multicenter cross-sectional study (Observatoire des pratiques médicales®) involving a cohort of children treated with Saizen®, a growth hormone.
The study does not require any changes to the usual medical management of these patients and should not be considered detrimental to their physical or psychological integrity. No specific procedures or examinations will be requested, nor does the protocol require any particular treatment or follow-up visits.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Already treated patients who are dissatisfied with their current self-injection device, or naïve pediatric patients, in cases for which this indication is validated (growth hormone deficiency, Turner's syndrome, chronic renal failure, small-for-gestational age \[SGA\] patients, based on RCP)
- Exclusion Criteria:
- • Cases in which Saizen® is contra-indicated (based on local RCP)
- • Children returning for consultation, who have not brought back their Easypod™ electronic self-injector.
- • Children who are participating in a therapeutic trial, or who have done so in the 3-month period preceding their recruitment into this observational study
About Merck Kgaa, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, is a leading global science and technology company, specializing in healthcare, life sciences, and performance materials. With a rich history dating back to 1668, Merck KGaA is committed to advancing innovative solutions that improve the quality of life for patients and drive scientific discovery. The company invests significantly in research and development to bring cutting-edge therapies to market, focusing on areas such as oncology, immunology, and neurology. As a dedicated clinical trial sponsor, Merck KGaA collaborates with healthcare professionals and institutions worldwide to conduct rigorous trials that ensure the safety and efficacy of its products, ultimately aiming to enhance patient outcomes and foster global health advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Clément Olivier, MD, LMCC
Study Director
Merck Serono S.A., Geneva
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials